Pipeline: What Alzheimer's Drugs Look Like in 2026 Beyond Amyloid

I am not in resident clinic this month. Which means, for the first time in a while, I have had time to sit with the journals rather than just scan them between placing orders and writing notes.

One article stopped me. Published just this week in FEBS Open Bio, researchers from King's College London reported pre-clinical results on a compound called KCL-286 — a drug that targets something most people have never considered in the context of Alzheimer's disease: DNA damage. Not amyloid. Not tau. The DNA inside the neurons themselves.

It struck me as exactly the kind of story worth telling, because it is also a lens through which to look at where the entire Alzheimer's drug development pipeline stands right now — a pipeline that is, in 2026, broader, more scientifically sophisticated, and more strategically diverse than at any point in history.

A Field That Has Learned From Its Failures

To appreciate where the pipeline is now, you have to understand where it has been.

For most of the last three decades, Alzheimer's drug development was organized almost entirely around a single hypothesis: that amyloid-beta — the sticky protein that accumulates in plaques between neurons — was the primary driver of the disease, and that clearing it would halt or reverse cognitive decline. Hundreds of trials. Billions of dollars. Failures that were sometimes spectacular in their margin.

The amyloid hypothesis was not wrong. It was incomplete. Leqembi and Kisunla — the two anti-amyloid immunotherapies now approved and in clinical use — proved that clearing amyloid can meaningfully slow the disease. But the effect size, roughly 30 to 35% reduction in the rate of decline, tells you something important: amyloid clearance alone leaves the majority of the disease's momentum unaddressed. The other 65 to 70% is driven by biology that anti-amyloid therapy does not reach. It is also important to say that right now Leqembi and Kisunla are the best we have.

The field has absorbed that lesson. The 2026 Alzheimer's Drug Development Pipeline report, published this spring in Alzheimer's & Dementia: Translational Research, catalogues 182 agents currently in active clinical trials. More than 70% of them target pathways entirely outside the amyloid cascade. This is not a retreat from the amyloid hypothesis. It is the evolution of a field that now understands Alzheimer's as a multi-pathway disease requiring a multi-target strategy — much the same intellectual shift that transformed oncology from single-drug chemotherapy to combination targeted therapy over the past thirty years.

The New Frontiers: What the Pipeline Is Actually Targeting

The sheer diversity of mechanisms now under investigation is striking when you look at the pipeline in aggregate.

Neuroinflammation is the single largest category in the current pipeline, with 28 agents in active trials addressing immune and inflammatory pathways. This reflects a genuine reorientation in how the field understands the disease. Alzheimer's is not simply a protein aggregation disorder — it is a chronic neuroinflammatory process in which the brain's immune cells, called microglia and astrocytes, become chronically overactivated and begin damaging the very neurons they are supposed to protect. Targeting the molecular triggers of that overactivation — including pathways involving TREM2, complement activation, and microglial senescence — has become one of the most active areas of investigation.

Tau biology accounts for 15 agents in current trials, reflecting growing recognition that tau pathology — the formation of neurofibrillary tangles — is more directly linked to neurodegeneration and symptom progression than amyloid alone. Anti-tau antibodies, tau aggregation inhibitors, and agents that reduce tau phosphorylation are all in the pipeline. This work is particularly relevant given what the EVOKE trials taught us: addressing amyloid without addressing tau leaves the neurodegenerative engine largely running.

Metabolism and bioenergetics represent another growing category, with seven agents targeting the energy crisis that occurs in Alzheimer's neurons. Brain cells in Alzheimer's disease show profound glucose hypometabolism — an inability to efficiently produce and use ATP — that precedes overt neurodegeneration. Agents aimed at improving mitochondrial function and providing alternative fuel sources for neurons represent a mechanistically distinct and compelling strategy.

Synaptic plasticity and neuroprotection — preserving the connections between neurons rather than just removing toxic proteins — account for eight agents, including several that target BDNF pathways, the same neurotrophin that I discuss regularly in the context of exercise and cognitive reserve.

The Article That Caught My Eye: Epigenetics and DNA Repair

Which brings me back to KCL-286 and the paper published this week.

To understand why this compound matters, you need a brief primer on what is happening at the DNA level in Alzheimer's neurons. As the disease progresses, amyloid-beta accumulates and suppresses the brain's natural retinoic acid signaling — a molecular pathway derived from vitamin A that plays a critical role in gene regulation and neuronal maintenance. When this signaling is disrupted, neurons lose their ability to repair DNA damage efficiently. The result is an accumulation of what are called DNA double-strand breaks — severe structural injuries to the genome that, if unrepaired, cause neurons to malfunction and eventually die.

This is not a peripheral finding. DNA double-strand breaks have been documented in post-mortem brain tissue from Alzheimer's patients, and the proteins responsible for repairing them — including BRCA1, better known for its role in breast cancer risk — have been found abnormally accumulated around the tau tangles characteristic of the disease.

KCL-286 addresses this directly. It is a small molecule that activates retinoic acid receptor-beta (RARβ), a protein that controls the expression of DNA repair genes. In the mouse model tested by the King's College London team, treatment with KCL-286 produced significantly fewer DNA double-strand breaks in neurons, increased expression of BRCA1, reduced microglial and astrocyte overactivation, and decreased neuroinflammation — addressing multiple disease-relevant pathways simultaneously through a single mechanism.

The lead researcher described it with an analogy that I found genuinely clarifying: the drug is like repairing potholes in a road. Once the damage is fixed, normal traffic can flow again and the system settles down.

What makes this particularly noteworthy from a development standpoint is that KCL-286 is not starting from zero. It was originally developed for spinal cord injury and has already successfully cleared Phase 1 human safety and tolerability trials. That safety profile dramatically accelerates the path to clinical testing in Alzheimer's patients — the researchers estimate it cuts years off the typical development timeline. Their next step is investigating whether the compound improves memory, cognition, and daily function in human Alzheimer's patients, and they have noted potential for combination use alongside existing anti-amyloid therapies like lecanemab.

This is precisely the combination therapy logic the field has been moving toward. Anti-amyloid drugs clear the protein. A DNA repair agent addresses the downstream cellular damage that continues even after the protein is cleared. Each layer of intervention addresses a different layer of the disease.

The Caveat: Mouse Models and the Road to Human Trials

I want to be honest here about something that matters for anyone reading this who may have a loved one with Alzheimer's or who is thinking about their own risk.

KCL-286 is a preclinical finding. The results in mice are genuinely encouraging, and the prior human safety data is a meaningful advantage. But the history of Alzheimer's drug development is littered with compounds that looked extraordinary in mouse models and failed to replicate in human trials. The biology of Alzheimer's in a mouse, even a well-designed transgenic model, is not the same as the biology of Alzheimer's in an 80-year-old human brain carrying decades of accumulated vascular disease, metabolic dysfunction, and mixed pathology.

This is not a reason to dismiss the finding. It is a reason to hold it with appropriate scientific humility — to be genuinely interested without being prematurely hopeful in a way that sets patients and families up for disappointment.

The same calibration applies to the broader pipeline. 182 agents in trials is a number that carries real promise. It also means that the vast majority of those agents will not make it to approval. That is not failure — it is how science works. Each failure teaches something that makes the next generation of trials more precise. The field is smarter about Alzheimer's today than it has ever been, and that accumulated intelligence is the foundation on which an eventual breakthrough will be built.

What This Means Right Now

For patients and families following this space, the practical implications of a pipeline update are straightforward.

The therapeutic landscape for Alzheimer's in 2026 is meaningfully better than it was five years ago and will almost certainly be meaningfully better again in five years. The anti-amyloid drugs that exist now are imperfect first-generation tools — much as the first beta-blockers were imperfect relative to what followed. The neuroinflammation agents, tau-targeting therapies, metabolic interventions, and epigenetic approaches now in trials represent the next generation.

The most actionable thing this pipeline news implies for patients today is the continued importance of clinical trial participation. Every drug in that pipeline of 182 agents requires human volunteers to test. For patients with early Alzheimer's or MCI, clinical trial enrollment is not just altruistic — it is frequently the best available access to the most current science, often accompanied by monitoring and care that exceeds what standard treatment provides.

And for those focused on prevention rather than treatment: the pipeline's growing emphasis on neuroinflammation, metabolic health, and cellular repair pathways maps directly onto the lifestyle levers discussed throughout this blog. Exercise reduces neuroinflammation. Sleep supports DNA repair through glymphatic clearance. Metabolic optimization preserves neuronal bioenergetics. The biology that pharmaceutical researchers are now targeting with drugs is the same biology that lifestyle intervention modifies — less potently, perhaps, but without a prescription, without side effects, and starting today.

Takeaways

The 2026 Alzheimer's pipeline contains 182 active agents, with more than 70% targeting pathways beyond amyloid — including neuroinflammation, tau biology, metabolism, synaptic plasticity, and epigenetic regulation. This represents the broadest and most mechanistically diverse pipeline in the history of Alzheimer's research.

KCL-286, published this week in FEBS Open Bio, represents a genuinely novel approach — targeting neuronal DNA damage and the retinoic acid signaling pathway that controls DNA repair. In mouse models, it reduced DNA double-strand breaks, increased BRCA1 expression, and decreased neuroinflammation. Having already passed Phase 1 human safety trials for spinal cord injury, it is positioned for accelerated testing in Alzheimer's patients.

Combination therapy is the direction the field is moving. Anti-amyloid drugs address one layer; agents targeting inflammation, tau, metabolism, and DNA repair address others. The oncology parallel — from single-drug to multi-target regimens — is the model the field is following.

Mouse model results require calibrated optimism. The history of Alzheimer's drug development demands intellectual humility about preclinical findings, however promising. KCL-286 is encouraging. It is not yet a treatment.

Clinical trial participation matters. For patients with early Alzheimer's or MCI, enrollment in trials is frequently the best available access to next-generation science and monitoring.

Citations and References

Hill N, AlMuallim A, et al. Treatment with KCL-286, a first-in-class retinoic acid receptor-β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease. FEBS Open Bio. 2026. https://doi.org/10.1002/2211-5463.70284

Cummings J, et al. Alzheimer's disease drug development pipeline: 2026. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2026. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70251

Cummings J, et al. Alzheimer's Disease: Novel Targets and Investigational Drugs for Disease Modification. Drugs. 2023. https://doi.org/10.1007/s40265-023-01938-w

Cummings J, et al. Alzheimer's disease drug development pipeline: 2025. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12131090/